IngredientesPlant sterols — also universally referred to as phytosterols — are triterpenes that are important structural components of plant membranes. Free phytosterols serve to stabilize phospholipid bilayers in plant cell membranes in precisely the same way that cholesterol does in animal cell membranes. The terms phytosterols and plant sterols are used interchangeably in the scientific literature. The related saturated forms are called stanols, plant stanols, or phytostanols — these three phrases are synonymous.
Sterols are a subgroup of steroids bearing a hydroxyl group at the C-3 position. Phytosterols generally have a double bond within the steroid nucleus, as cholesterol does; however, phytosterols are also characterized by a substituted side chain at C-24, such as an ethyl or methyl group, or an additional double bond. Most phytosterols contain 28 or 29 carbons and one or two carbon-carbon double bonds, typically one in the sterol nucleus and sometimes a second in the alkyl side chain. Phytostanols are a fully saturated subgroup of phytosterols, containing no double bonds.
The chemical structure of these plant sterols is very similar to that of cholesterol, with differences occurring in the side chain of the backbone of the molecule. For example, compared to cholesterol, the side chain of sitosterol contains an additional ethyl group, and the side chain of campesterol contains an additional methyl group. These structural differences render phytosterols minimally absorbable in the intestine — approximately 0.5–2% for plant sterols. As a result of low absorption and efficient excretion after uptake by the liver, circulating levels are low, varying from 0.3–1.0 mg/dL for plant sterols.
At least 44 naturally occurring phytosterols have been discovered, and they are generally derived from plants such as corn, soy, wheat, and wood oils; however, they can also be produced synthetically to form compositions identical to those found in nature.
Non-limiting examples of phytosterols well established in the scientific literature include 4-desmethyl sterols such as β-sitosterol, campesterol, stigmasterol, brassicasterol, 22-dehydrobrassicasterol, and Δ5-avenasterol; 4-monomethyl sterols; and 4,4-dimethyl sterols (triterpene alcohols) such as cycloartenol, 24-methylenecycloartanol, and cyclobranol.
The most abundant plant sterols in the flora are β-sitosterol, campesterol, and stigmasterol. In decreasing relative abundance across vegetable oil samples, the major phytosterols are: β-sitosterol (range 28–55% of total sterol content), Δ5-avenasterol (3–24%), campesterol (2–33%), Δ5-stigmasterol (0.7–18%), Δ7-stigmasterol (1–18%), and Δ7-avenasterol (0.1–5%).
Phytostanols are the saturated forms of phytosterols in which the C-5 and, when present, C-22 double bonds are reduced; they include sitostanol, campestanol, and 22-dihydrobrassicastanol. Phytosterol esters and phytostanol esters are further characterized by the presence of a fatty acid or phenolic acid moiety rather than a hydroxyl group at the C-3 position.
Plant sterols and stanols are present naturally in small quantities in many fruits, vegetables, nuts, seeds, cereals, legumes, vegetable oils, bark of trees, and other plant sources. Phytosterols are found in all plant foods, but the highest concentrations are found in unrefined plant oils, including vegetable, nut, and olive oils. Nuts, seeds, whole grains, and legumes are also good dietary sources of phytosterols.
The total phytosterol content is highest in vegetable oils (150.4–1,230.9 mg/100 g), followed by legumes (129.6–275.6 mg/100 g), nuts (18.9–255.2 mg/100 g), and cereals (11.9–93.8 mg/100 g). These compounds, both in their free form and as esters, glycosides, or acyl glycosides, are natural components of nuts, seeds, edible oils, and vegetables. Their total content in plant oils varies and ranges, for example, from 0.4 mg/g in Nigella sativa oil to 13.8 mg/g in crude rice bran oil.
Unlike the typical diet in most developed countries today, the diets of ancestral human populations were rich in phytosterols, likely providing as much as 1 g/day. Present-day dietary phytosterol intakes have been estimated to vary from 150 to 450 mg/day in different populations. Vegetarians, particularly vegans, generally have the highest intakes of dietary phytosterols.
As functional additives to food products, free phytosterols or their esters (PE) with fatty acids are used. Phytosterols can also be converted to phytostanols by chemical hydrogenation. A variety of foods containing added plant sterols or stanols — including margarines, mayonnaises, vegetable oils, salad dressings, yogurt, milk, soy milk, orange juice, snack bars, and meats — are available in the United States, Europe, Asia, Australia, and New Zealand.
Because of their inert crystalline structure, pure plant sterols and stanols are not consistently effective in lowering cholesterol absorption and must be adequately formulated before use. The most accepted method to optimize their effect on cholesterol absorption is esterification to fatty acids and dissolving plant sterols/stanols within food fats. Some studies have also shown that free plant sterols/stanols when mixed with fat spread are effective in reducing LDL cholesterol levels.
Historically, the distinction between plant sterols and cholesterol has been recognized for a century or more, and the fact that plant sterols were not substantially absorbed by the body has been investigated for almost half a century.
Plant sterols have been known since the 1950s as bioactive compounds that lower cholesterol levels in human blood. The oral administration of plant sterols in gram quantities was shown to interfere with cholesterol absorption and is one of the oldest pharmacological therapies for hypercholesterolemia. In the early 1950s, plant-derived sterols were observed to decrease serum cholesterol levels, with the effective dose in humans reported to be between 5 and 10 g/day when given in divided doses.
Although the basis for this cholesterol-lowering effect was shown to be caused by the exclusion of cholesterol from intestinal micelles by plant sterols, it was not until the identification of a rare genetic disease — sitosterolemia, first described in 1974 — that led to the hypothesis that specific molecular mechanisms govern both the entry and excretion of sterols by the body.
The pharmacological use of plants and herbs (phytotherapy) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia has been growing steadily. Phytotherapeutic preparations containing beta-sitosterols, derived from the South African star grass Hypoxis rooperi, or from species of Pinus and Picea, have been available for the treatment of BPH.
Unlike the typical diet in most developed countries today, the diets of ancestors were rich in phytosterols, likely providing as much as 1 g/day. As plant foods — particularly unrefined grains, legumes, nuts, and plant oils — formed the dietary cornerstone of most traditional human cultures worldwide, plant sterols were consumed as an inherent part of traditional diets long before their identification as discrete chemical compounds.
β-Sitosterol is the most abundant plant sterol, typically representing 28–55% of the total sterol content in vegetable oils. It is also the most extensively studied individual phytosterol. Campesterol and stigmasterol are the next most abundant, followed by Δ5-avenasterol. Phytostanols occur in trace levels in many plant species and in high levels in tissues of only a few cereal species.
Phytosteryl esters are endogenous edible oil components present in the range of 6% to 68% of the total sterol content and are predominantly found in canola/rapeseed, corn, peanut, avocado, evening primrose, and sunflower oils. Phytosterols are mainly esterified in most common foods except in nuts.
Plant sterols impair cholesterol absorption from the bowel via different mechanisms: by competing with dietary and biliary cholesterol for micellar solubilization in the intestinal lumen, impairing intestinal cholesterol absorption, and altering the conversion of bile acids into secondary bile acids.
The initial stage of intestinal handling of phytosterols from the diet is essentially similar to the absorption of cholesterol, involving emulsification, hydrolysis, and micellar transport. However, most plant sterols/stanols are pumped back into the gut lumen via the ATP-binding cassette co-transporters G5 and G8 (ABCG5/ABCG8), resulting in the minimal entry of these plant-derived molecules into the circulation. The hypocholesterolemic effects of plant sterols/stanols are explained by inhibition of cholesterol absorption, ascribed primarily to competition with intestinal cholesterol for incorporation into mixed micelles, although other mechanistic explanations have been proposed.
Inhibition of the intestinal absorption of both exogenous (dietary) and endogenous (biliary) cholesterol is the main underlying mechanism for the cholesterol-lowering effect of plant sterols and stanols. Based on current knowledge, plant sterols/stanols reduce solubilization of cholesterol in micelles and may also affect the site of absorption and intracellular trafficking of cholesterol.
The mechanisms by which plant sterols display their anti-inflammatory activity are thought to include inhibition of the secretion of inflammatory mediators such as interleukin-6 and tumor necrosis factor-α by monocytes.
Beta-sitosterol (BSS) and its glycoside (BSSG) are sterol molecules synthesized by plants. When humans consume plant foods, phytosterols are ingested and are found in the serum and tissues of healthy individuals, but at concentrations orders of magnitude lower than endogenous cholesterol.
Functional foods enriched with plant sterols/stanols have become the most widely used nonprescription cholesterol-lowering approach, despite the lack of randomized trials investigating their long-term safety and cardiovascular efficacy. The cholesterol-lowering effect of plant-sterol supplementation is well-established, and a potential beneficial impact on other lipoproteins and glucose homeostasis has been described.
Meta-analyses and systematic reviews: A meta-analysis that identified 59 eligible randomized clinical trials published from 1992 to 2006, using weighted mean effect sizes calculated with a random-effects model, found that plant sterol-containing products decreased LDL levels by 0.31 mmol/L (95% CI: −0.35 to −0.27, P < 0.0001) compared with placebo.
A further meta-analysis of 124 studies (201 strata) included plant sterols and stanols administered in 129 and 59 strata respectively. The average phytosterol dose was 2.1 g/day (range 0.2–9.0 g/day). Intakes of 0.6–3.3 g/day were found to gradually reduce LDL-cholesterol concentrations by, on average, 6–12%. When plant sterols and stanols were analysed separately, clear and comparable dose-response relationships were observed. Studies carried out with doses exceeding 4 g/day were not pooled, as these were scarce and scattered across a wide range of doses. The LDL-cholesterol-lowering effect of both plant sterols and stanols continues to increase up to intakes of approximately 3 g/day, with an average effect of 12%.
A meta-analysis of 41 trials showed that intake of 2 g/day of stanols or sterols reduced LDL by 10%; higher intakes added little additional benefit. Efficacy is similar for sterols and stanols, but the food form may substantially affect LDL reduction. Effects are additive with dietary or drug interventions: eating foods low in saturated fat and cholesterol and high in stanols or sterols can reduce LDL by 20%; adding sterols or stanols to statin medication is more effective than doubling the statin dose.
A 2023 systematic review and meta-analysis further confirmed this body of evidence: from a total of 223 studies, 125 were included. On average, phytosterols lowered LDL-C by 0.55 mmol/L (95% CI = 10.82–12.67%), and this decrease was significantly maintained for all analysed subgroups. A greater reduction in LDL-C levels was detected in relation to a higher daily phytosterol dosage.
Effect modifiers: Reductions in LDL levels were greater in individuals with high baseline LDL levels compared with those with normal to borderline levels. Reductions were greater when plant sterols were incorporated into fat spreads, mayonnaise and salad dressing, milk and yogurt compared with other food products such as croissants, muffins, orange juice, non-fat beverages, cereal bars, and chocolate. Plant sterols consumed as a single morning dose did not have a significant effect on LDL cholesterol levels. In summary, the reduction was related to individuals' baseline LDL levels, food carrier, and frequency and time of intake.
Regulatory recognition of the evidence: Based on the totality of publicly available evidence, the U.S. FDA concluded that plant sterol/stanol esters may reduce the risk of coronary heart disease, issuing an interim final rule in September 2000. The level of plant sterol esters necessary to justify a health claim is 1.3 g per day, according to FDA.
EFSA's Panel on Dietetic Products, Nutrition and Allergies (NDA) found that sterols and stanols were equally efficient in LDL lowering. The NDA stated that dosages between 1.5–1.9 g/day of stanols/sterols could lower LDL cholesterol levels by 8.5%, while daily dosages between 2–2.4 g/day could reduce cholesterol by 8.9%. Across the full dose range of 1.5–2.4 g/day, an average reduction of between 7 and 10.5% was observed. The Panel considered this reduction to be of biological significance in terms of reduced risk of coronary heart disease.
EFSA noted that a cholesterol-lowering effect could usually be observed after 2–3 weeks, with effects demonstrated ongoing in studies lasting up to 85 weeks.
Apolipoprotein effects: A large meta-analysis of 37 randomized clinical trials with 51 arms has shown that phytosterols increase plasma levels of Apo A-I and Apo C-II, and decrease Apo B-100, the Apo B-100/Apo A-I ratio, and Apo E, without affecting plasma levels of Apo A-II and Apo C-III.
Evidence strength assessment: The cholesterol-lowering effect of plant sterols is among the most robustly replicated findings in dietary supplement research, supported by dozens of randomized controlled trials and multiple independent meta-analyses, and has earned formal regulatory health claims from both the U.S. FDA and the European Union's EFSA. The evidence base is strong for short-term surrogate outcomes (LDL cholesterol). Long-term randomized evidence on hard cardiovascular events (myocardial infarction, stroke, cardiovascular mortality) is, however, absent.
Sterol-enriched diets (≥2 g/day) may decrease total and low-density lipoprotein cholesterol concentrations by 5–10%, either alone or when added to statins, since they antagonize dietary cholesterol absorption in the intestine. A population-based study conducted in Poland (n = 5,690) showed that habitual dietary intake of plant sterols may be associated with a lower chance of developing atherosclerotic cardiovascular disease (ASCVD), particularly in men. However, functional foods enriched with plant sterols/stanols have become the most widely used nonprescription cholesterol-lowering approach, despite the lack of randomized trials investigating their long-term safety and cardiovascular efficacy.
Phytotherapeutic preparations containing beta-sitosterols, derived from the South African star grass Hypoxis rooperi, or from species of Pinus and Picea, have been available for the treatment of BPH.
The most rigorous systematic review of beta-sitosterols for BPH was undertaken in 1999 by Wilt and colleagues, encompassing three different products — Harzol, Azuprostat, and WA184 — all of which contain different amounts of β-sitosterol. Five hundred and nineteen men from four randomized, placebo-controlled, double-blind trials (lasting 4–26 weeks) were assessed. Three trials used nonglucosidic β-sitosterols, and one utilized a preparation that contained 100% beta-sitosteryl-β-d-glucoside. Two of the four studies reported an improvement in International Prostate Symptom Score (IPSS) of roughly 35% over placebo.
The weighted mean difference for the IPSS was −4.9 IPSS points (95% CI = −6.3 to −3.5, n = 2 studies). The weighted mean difference for peak urine flow was 3.91 mL/sec (95% CI = 0.91 to 6.90, n = 4 studies) and the weighted mean difference for residual volume was −28.62 mL (95% CI = −41.42 to −15.83, n = 4 studies). The trial using 100% beta-sitosteryl-β-d-glucoside also showed improvement in urinary flow measures. Beta-sitosterols did not reduce prostate size.
The Cochrane reviewers' conclusions were that the evidence suggests non-glucosidic beta-sitosterols improve urinary symptoms and flow measures; however, their long-term effectiveness, safety, and ability to prevent BPH complications are not known.
A randomized, double-blind, placebo-controlled clinical trial assessed the efficacy and safety of 130 mg free beta-sitosterol daily, using the IPSS as the primary outcome variable. In total, 177 patients with BPH were recruited for 6 months of treatment in 13 study centres; secondary outcomes included changes in quality of life, peak urinary flow rate, and post-void residual urinary volume. The drug used consisted of a chemically defined extract of phytosterols derived from species of Pinus, Picea, or Hypoxis, with beta-sitosterol as the main component.
Evidence strength assessment: The evidence for beta-sitosterol in BPH is moderate — supported by a Cochrane systematic review of randomized controlled trials showing statistically significant improvements in urinary symptoms and flow measures. Important limitations are the short duration of trials (4–26 weeks), the lack of data on prostate size reduction or long-term BPH complications, and heterogeneity between products used.
Several animal and human studies report reductions in the levels of proinflammatory cytokines, including C-reactive protein, after consumption of dietary plant sterols. Although the cholesterol-lowering effects of phytosterols in humans are well documented, studies on the effects of phytosterols on inflammatory markers have produced inconsistent results.
A meta-analysis summarizing available evidence showed that foods with added plant sterols (average plant sterol dose: 2.2 g/day) overall did not significantly affect C-reactive protein (CRP). Other inflammatory markers also showed no overall effect. However, this meta-analysis did observe a significant dose-response relationship for the effect of plant sterols on CRP, implying that higher plant sterol doses (≥3 g/day) may be needed for a significant anti-inflammatory effect.
Findings on the effects of plant sterols on inflammation remain limited and confounding. Future research using better-designed and well-controlled laboratory studies and clinical trials are needed to fully understand the mechanisms through which phytosterols influence inflammation.
Evidence strength assessment: Evidence for anti-inflammatory effects is currently weak to preliminary in humans. Meta-analyses do not show a significant overall reduction in CRP at typical doses. A possible dose-dependent effect at higher doses has been signalled but not definitively established.
In animals, beta-sitosterol (BSS) and its glycoside (BSSG) have been shown to exhibit anti-inflammatory, anti-neoplastic, anti-pyretic, and immune-modulating activity. Bouic and colleagues have reviewed possible roles of phytosterols in the etiology or prevention of various diseases and conditions, including proliferative responses of lymphocytes, pulmonary tuberculosis, feline immunodeficiency virus and HIV, stress-induced immune suppression, rheumatoid arthritis, and allergic rhinitis/sinusitis. Most of this work has been conducted with animals. Human clinical evidence for immune-modulating claims is very limited in quantity and quality.
It has been established that a diet rich in plant sterols or their esters alleviates cardiovascular diseases (CVD), and it may also inhibit breast, colon, and lung carcinogenesis. Awad and colleagues demonstrated the capability of β-sitosterol to suppress growth and to induce apoptosis in MDA-MB-231 breast cancer cells, suggesting a potential role for dietary constituents as adjuvant therapy. A 66% reduction in cell growth was noted following β-sitosterol treatment in one study, and an 87% reduction in breast cancer cell growth in a related study using the estrogen-responsive MCF-7 cell line. The persistence of these effects despite differences in estrogen responsiveness between the two cell lines suggests additional non-hormonal effects of plant sterols.
Evidence strength assessment: All available anticancer evidence remains at the in vitro (cell culture) and animal model level. No human clinical trials have established a therapeutic or preventive anticancer role for plant sterols. The existing preclinical data are hypothesis-generating only.
In a double-blind, randomized, placebo-controlled, parallel study, 161 individuals at increased risk of and with established type 2 diabetes mellitus consumed low-fat spreads without or with added plant sterols (2 g/day) for 6 weeks after a 2-week run-in period.
In a 200-participant, 12-week factorial design randomized controlled trial, the group receiving plant sterols alone was only associated with decreased triglycerides and high-sensitivity C-reactive protein. No plant sterol interventions produced significant changes in body weight, BMI, blood pressure, fasting insulin, body fat percentage, visceral fat rating, total cholesterol, LDL-cholesterol, or interleukin-6.
Evidence strength assessment: Evidence for beneficial effects of plant sterols on glycemic parameters is very limited and not consistently demonstrated in available trials. Plant sterols have a documented lipid-lowering effect in people with type 2 diabetes similar to that seen in the general population, but direct anti-diabetic effects on glucose and insulin parameters are not established.
A variety of foods containing added plant sterols or stanols — including margarines, mayonnaises, vegetable oils, salad dressings, yogurt, milk, soy milk, orange juice, snack bars, and meats — are available across multiple regions.
The following dosages have been reported in, or established by reference to, specific studies and regulatory bodies:
Plant sterol esters were approved as Generally Recognized As Safe (GRAS) by the U.S. FDA for use in margarines and spreads in 1999. In September 2000, the FDA also issued an interim rule that allows health-claims labeling of foods containing phytosterol esters.
Plant sterol supplementation can increase serum plant sterol levels, but these remain much lower than levels seen in sitosterolemia, making adverse health effects from supplementation at recommended doses unlikely. There is also a small reduction in serum beta-carotene levels, but this is not considered a major health concern. Studies have not shown significant adverse effects on fat-soluble vitamins, sex hormone metabolism, or other metabolic processes at typical doses.
Since plant sterols and plant stanols interfere with intestinal cholesterol absorption and consequently affect whole-body lipid and lipoprotein metabolism, questions have been raised about whether plasma fat-soluble vitamin and carotenoid concentrations are also affected. A reduction in plasma fat-soluble vitamin and carotenoid concentrations may be undesirable, since in prospective cohort studies lower concentrations have been associated with an increased risk of several chronic diseases.
Forty-one randomized controlled trials involving 3,306 subjects were included in one meta-analysis examining this question. A meta-analysis of 10–15 trials per vitamin showed that plasma levels of vitamins A and D are not affected by stanols or sterols. Alpha-carotene, lycopene, and vitamin E levels remained stable relative to their carrier molecule, LDL.
Plant sterols reduce the absorption of the fat-soluble vitamins beta-carotene, alpha-carotene, and vitamin E; no effects on vitamins A and K have been noted in the clinical literature. The main side effect reported is a reduction in the ratio of β-carotene to LDL cholesterol and lycopene values, which could be balanced by increasing the intake of fruits and vegetables, especially those rich in carotenoids.
Sitosterolemia is a rare autosomal recessively inherited disorder that results from the absorption of high amounts of plant sterols and cholesterol, linked to a locus at chromosome 2p21, leading to the development of coronary heart disease at a young age and the development of tendon xanthomatosis. Patients with sitosterolemia, a condition in which high plasma concentrations of plant sterols can lead to tendon xanthomas, premature atherosclerosis, and hemolytic anemia, should avoid plant sterols. Sitosterolemic persons should avoid food products containing plant sterols.
Regular consumption of plant sterol-enriched foods can increase blood levels of plant sterols such as sitosterol and campesterol, though these increases are much lower than those seen in the rare genetic condition sitosterolemia. Stanol-enriched foods do not cause the same increase in blood sterol levels. Increased serum phytosterol concentrations may contribute to atherosclerotic risk, although a threshold for such a role has not been established.
Worsening of liver function has been reported for a person with short bowel syndrome who was given nutrients containing plant sterols. Liver function improved when the plant sterols were removed from the nutrients; it is not clear whether the plant sterols were responsible. Until more is known, plant sterols should not be taken by those with short bowel syndrome.
Medications such as ezetimibe may effectively reduce both cholesterol and phytosterol absorption. Beta-sitosterol levels may decrease in patients receiving ezetimibe through its inhibition of intestinal absorption of plant sterols.
Adding sterols or stanols to statin medication is more effective at lowering LDL than doubling the statin dose, indicating a complementary rather than antagonistic interaction with statins. However, this pharmacodynamic combination should be understood in terms of the additive LDL-lowering effect, not as a replacement for medication management.
Beta-sitosterol should be avoided in pregnant women due to demonstrated uterine stimulant effects.
Until long-term studies are performed to ensure the absence of adverse effects in all individuals ingesting plant sterol esters, these products have been recommended to be reserved for adults requiring lowering of total and LDL cholesterol levels because of hypercholesterolemia or for secondary prevention after an atherosclerotic event. Although use as a dietary adjunct in moderate to severely hypercholesterolemic children can be considered, fat-soluble vitamin status should be monitored, and long-term safety studies are required. Whether plant sterols should be used in normocholesterolemic individuals with other risk factors for coronary heart disease remains to be determined.
There are only a few studies in which cholesterol-lowering effects of plant stanols have been studied with doses higher than commonly used. In these studies with a stanol dose of 4 g/day, no additional cholesterol-lowering effect was demonstrated. The evidence therefore supports a practical upper limit for cholesterol-lowering benefit at approximately 3 g/day, with little added advantage at higher doses.
Condiciones de salud que esteroles vegetales puede ayudar a apoyar.
Plant sterols reduce LDL cholesterol by 5–15% at 2–3 g/day by competitively displacing cholesterol from intestinal micelles. EFSA, FDA, and WHO endorse them for LDL reduction and cardiovascular risk management. Reducing atherogenic LDL directly reduces arterial plaque progression. Clinical trials have also directly assessed their effects on arterial stiffness.
Emerging clinical evidence suggests plant sterols can modestly lower blood pressure in individuals with metabolic syndrome when combined with a healthy dietary pattern. One 12-week crossover RCT in adults with metabolic syndrome found significant blood pressure reduction and improved endothelial function with 2 g/day of plant sterol-enriched soy milk. Evidence outside of a metabolic syndrome context is limited.
Evidence for plant sterols on glycemic markers is limited and mixed. The most direct signal comes from a 12-week RCT where plant sterols alone reduced TG and hs-CRP in individuals with impaired glucose regulation, but had no significant independent effect on fasting blood glucose, insulin, or HbA1c. A systematic review and meta-analysis found conflicting results across trials for blood glucose and insulin outcomes.
Plant sterols competitively inhibit intestinal cholesterol absorption and consistently lower LDL-C by 8–15% at 2–3 g/day. EFSA and major dyslipidemia guidelines recognize their LDL-lowering health claim.
Plant sterols have demonstrated anti-inflammatory properties in some human studies, primarily through reductions in CRP and pro-inflammatory cytokines, though clinical results are inconsistent. A meta-analysis noted a significant dose-response relationship for CRP reduction, suggesting higher doses (≥3 g/day) may be required for a meaningful anti-inflammatory effect. In vitro and animal evidence is stronger than the clinical data.
Plant sterols have robust clinical trial and meta-analysis support for lowering LDL cholesterol, a key cardiovascular risk factor, primarily by competitively inhibiting cholesterol absorption in the small intestine. At approximately 2 g/day, they reduce LDL-C by 8–10%, and both the FDA and ESC/EAS guidelines recognize this effect. However, no large RCT has demonstrated a reduction in hard cardiovascular endpoints (e.g., heart attacks), and emerging genetic evidence raises questions about whether elevated circulating plant sterol levels may carry atherogenic risk.
Plant sterols address several components of metabolic syndrome, particularly elevated LDL-C and triglycerides. Clinical studies in individuals with metabolic syndrome show significant reductions in LDL-C and triglycerides, and one RCT also found blood pressure benefits when combined with a healthy dietary pattern. Effects appear more pronounced in metabolic syndrome patients than in normolipidemic subjects.
Beta-sitosterol, the predominant plant sterol in most supplements, has robust clinical evidence for improving lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). A Cochrane systematic review of four RCTs confirmed significant improvement in urologic symptom scores and urinary flow measures. Proposed mechanisms include 5-alpha-reductase inhibition and anti-inflammatory effects on prostate tissue.
Plant sterols, specifically beta-sitosterol, have been evaluated in multiple RCTs for BPH-related urinary symptoms. The Cochrane review confirmed improvements in urinary symptom scores and peak flow rate but found no significant reduction in prostate volume. Improvements in peak urinary flow and post-void residual volume are the most consistently demonstrated outcomes.
Plant sterols demonstrate a modest but documented triglyceride-lowering effect, particularly in individuals with elevated baseline triglycerides or metabolic syndrome. A meta-analysis of 12 studies found a significant 6% TG reduction at intakes of 1.6–2.5 g/day, with more pronounced effects in those with hypertriglyceridemia. The mechanism involves reduced hepatic VLDL secretion.
Sistemas corporales que esteroles vegetales puede ayudar a apoyar.
Volver